Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California. Show more

1800 Owens Street, San Francisco, CA, 94158, United States

https://www.vir.bio

Biotechnology

Healthcare

Start AI Chat

Market Cap

1.515B

52 Wk Range

$4.16 - $10.94

Previous Close

$9.48

Open

$9.61

Volume

2,612,536

Day Range

$9.12 - $9.73

Enterprise Value

1.146B

Cash

467M

Avg Qtr Burn

-25.88M

Insider Ownership

9.44%

Institutional Own.

70.18%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Tobevibart + Elebsiran Details Hepatitis Delta Virus	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sotrovimab VIR-7831 (GSK4182136) Details COVID-19, Infectious disease	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tobevibart (VIR-3434) + Elebsiran (VIR-2218) Details Infectious disease, Hepatitis B	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VIR-3434 +/- VIR-2218 +/- PEG-IFNα Details Infectious disease, Hepatitis B	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VIR-2482 (Universal prophylaxis) Details Influenza, Infectious disease	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VIR-5525 Details Cancer, Head and neck squamous cell carcinoma, Non-small cell lung carcinoma, Metastatic colorectal cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VIR-5818 + Pembrolizumab Details Cancer, HER2-expressing cancers, Metastatic breast cancer, Metastatic colorectal cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VIR-5500 + ARPIs Details Metastatic castration resistant prostate cancer (mCRPC)	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VIR-1388 (HVTN 142) Details Infectious disease, Human immunodeficiency virus, Vaccine	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VIR-1111 Details Infectious disease, Human immunodeficiency virus, Vaccine	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sotrovimab VIR-7831 (GSK4182136) Details COVID-19, Infectious disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.